

Table S4. Clinical characteristics and association with drug survival of the 247 PS patients' ANTI-TNF.

Characteristic		Drug Survival (months)- ANTI-TNF (N=247)							
		N	Events	MST (mo)	IC95%	Log-Rank p-value	Univariate Cox Model		
							HR	IC95%	p-value
Gender	Female	122	97	19	12-28	0.1			
	Male	125	96	30	20-44				
Age at baseline		197	150	-	-	-	0.987	0.97-0.99	0.041
	<54 years	93	75	17	12-32	0.09	1		
	>54 years	104	75	24	15-38		0.754	0.54-1.04	0.088
BMI at baseline		245	192	-	-	-	1.029	1.00-1.01	0.023
	Normal weight	78	58	36	19-54	0.3			
	Overweight	90	72	24	18-37				
	Obesity type I	45	35	23	11-30				
	Obesity type II	17	13	9	7-NA				
	Obesity type III	11	10	12	11-NA				
	Comorbidities								
	Psoriatic Arthritis	129	108	24	17-30	0.2			
	Hypertension	96	79	27	19-37	0.6			
	Dyslipidemia	111	88	29	20-38	0.6			
	Other comorbidities	160	126	23	16-30	0.1			
Age diagnosis PS		247	193	-	-	-	0.999	0.99-1.01	0.871
Family history PS		133	102	30	23-37	0.2			
Type of PS	Plaque	231	181	24	19-31	0.8			
	Other types PS	16	12	13	3-NA				
Bio-naive	Yes	138	101	31	24-46	0.007	1		
	No	109	92	15	11-26		1.473	1.10-1.95	0.007
Treatment line general		247	193	-	-	-	1.099	1.01-1.19	0.033
Concomitant Treatment	Acitretin	2	0	NA	NA-NA	0.02	9.4*10 ⁻⁸	0-Inf	0.991
	Cyclosporine	4	4	9.5	5-NA		1.29	0.47-3.5	0.614
	Methotrexate	32	26	29	12-50		0.957	0.62-1.46	0.839
	Topics	55	34	37	24-110		0.611	0.41-0.89	0.01
	Monotherapy (No)	154	129	19	14-27		1		
Adherent BT	Yes	195	152	24	18-30	0.3			
	No	47	36	38	11-56				
Baseline PASI		132	93	-	-	-	1.011	0.99-1.03	0.351
	<10	68	45	29	11-53	0.4			
	>10	64	48	23	13-37				
MST: median survival time (months); HR: hazard ratio; IC95%: 95% confidence interval; NA: not achieved. Anti-TNF: Tumour Necrosis Factor inhibitor (adalimumab, certolizumab pegol, etanercept and infliximab); BMI: Body Mass Index; BT: Biological therapy; PASI: Psoriasis Area Severity Index; PS: Psoriasis.									
Statistically significant values are colored in grey, with a tendency to significance in bold.									